Advertisement
CERS vs RDNT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and RDNT is a Hold.
CERS's RSI Oscillator climbs out of oversold territory
The RSI Indicator for CERS moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 22 of the 28 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CERS as a result. In 78 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for CERS just turned positive on October 20, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in 32 of 44 cases over the following month. The odds of a continued upward trend are 73%.
Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 170 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CERS broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CERS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.878) is normal, around the industry mean (2.923). P/E Ratio (-79.667) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
RDNT in +1.23% Uptrend, growing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RDNT advanced for three days, in 233 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 59 cases where RDNT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RDNT as a result. In 64 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for RDNT turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 42 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
RDNT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RDNT crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for RDNT entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.912) is normal, around the industry mean (64.450). RDNT's P/E Ratio (-263.115) is considerably lower than the industry average of (2.086). Projected Growth (PEG Ratio) (0.260) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.567) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. RDNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CERS | RDNT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 47 | |
SMR RATING 1..100 | 94 | 91 | |
PRICE GROWTH RATING 1..100 | 57 | 47 | |
P/E GROWTH RATING 1..100 | 19 | 56 | |
SEASONALITY SCORE 1..100 | n/a | 41 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RDNT's Valuation (1) in the Medical Or Nursing Services industry is in the same range as CERS (8) in the Medical Specialties industry. This means that RDNT’s stock grew similarly to CERS’s over the last 12 months.
RDNT's Profit vs Risk Rating (47) in the Medical Or Nursing Services industry is somewhat better than the same rating for CERS (100) in the Medical Specialties industry. This means that RDNT’s stock grew somewhat faster than CERS’s over the last 12 months.
RDNT's SMR Rating (91) in the Medical Or Nursing Services industry is in the same range as CERS (94) in the Medical Specialties industry. This means that RDNT’s stock grew similarly to CERS’s over the last 12 months.
RDNT's Price Growth Rating (47) in the Medical Or Nursing Services industry is in the same range as CERS (57) in the Medical Specialties industry. This means that RDNT’s stock grew similarly to CERS’s over the last 12 months.
CERS's P/E Growth Rating (19) in the Medical Specialties industry is somewhat better than the same rating for RDNT (56) in the Medical Or Nursing Services industry. This means that CERS’s stock grew somewhat faster than RDNT’s over the last 12 months.
| CERS | RDNT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 73% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 73% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 75% |
| Advances ODDS (%) | 2 days ago 75% | 3 days ago 74% |
| Declines ODDS (%) | 15 days ago 83% | 15 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 90% | N/A |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CERS’s FA Score shows that 2 FA rating(s) are green while RDNT’s FA Score has 1 green FA rating(s).
- CERS’s FA Score: 2 green, 3 red.
- RDNT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CERS’s TA Score shows that 4 TA indicator(s) are bullish while RDNT’s TA Score has 1 bullish TA indicator(s).
- CERS’s TA Score: 4 bullish, 4 bearish.
- RDNT’s TA Score: 1 bullish, 7 bearish.
Price Growth
CERS (@Medical/Nursing Services) experienced а +6.70% price change this week, while RDNT (@Medical Specialties) price change was -1.08% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.66%. For the same industry, the average monthly price growth was -7.04%, and the average quarterly price growth was +41.88%.
Reported Earning Dates
CERS is expected to report earnings on Nov 02, 2026.
RDNT is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.66% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
RDNT and
Correlation & Price change
A.I.dvisor indicates that over the last year, RDNT has been loosely correlated with ITGR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RDNT jumps, then ITGR could also see price increases.
| Ticker / NAME | Correlation To RDNT | 1D Price Change % | ||
|---|---|---|---|---|
| RDNT | 100% | -1.78% | ||
| ITGR - RDNT | 49% Loosely correlated | N/A | ||
| GKOS - RDNT | 48% Loosely correlated | +1.97% | ||
| NNOX - RDNT | 46% Loosely correlated | -6.87% | ||
| ICUI - RDNT | 43% Loosely correlated | -0.15% | ||
| CERS - RDNT | 42% Loosely correlated | +3.46% | ||
More | ||||